Randomized Controlled Trial
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2017; 8(7): 381-389
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods
Vikas Sood, Anil Bhansali, Bhagwant Rai Mittal, Baljinder Singh, Neelam Marwaha, Ashish Jain, Niranjan Khandelwal
Vikas Sood, 2nd Nuclear Medicine Centre, RCC, Indira Gandhi Medical College, Shimla 171001, India
Vikas Sood, Bhagwant Rai Mittal, Baljinder Singh, Departments of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Anil Bhansali, Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Neelam Marwaha, Ashish Jain, Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Niranjan Khandelwal, Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Sood V, Bhansali A and Mittal BR designed the research; Sood V and Jain A conducted the research; Singh B and Khandelwal N contributed analytic tools; Sood V and Bhansali A wrote the paper; all the authors contributed to this article.
Institutional review board statement: The study was reviewed and approved by Institutional Review Board of Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Clinical trial registration statement: This study is registered at (ClinicalTrials.gov). The registration identification number is (NCT01694173).
Informed consent statement: All study participants, or their legal guardian, provided informed legal consent prior to study enrolment.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at vikasvineeta@rediffmail.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Vikas Sood, MBBS, DRM, PhD, Assistant Professor, 2nd Nuclear Medicine Centre, RCC, Indira Gandhi Medical College, Circular Road, Shimla 171001, India. vikasvineeta@rediffmail.com
Telephone: +91-973-6657577 Fax: +91-017-72883401
Received: October 27, 2016
Peer-review started: October 31, 2016
First decision: December 1, 2016
Revised: February 9, 2017
Accepted: April 23, 2017
Article in press: April 24, 2017
Published online: July 15, 2017
Processing time: 248 Days and 14.5 Hours
Core Tip

Core tip: Homing of stem cells to pancreas is an important pre-requisite for achieving therapeutic efficacy in type 2 diabetes mellitus patients. Homing of stem cells was demonstrated when targeted infusion was carried out. No discernible homing was there when intravenous infusion route was employed. It was only in the targeted group that a 50% reduction in Insulin dosage was observed, establishing a relationship between homing and therapeutic efficacy.